BSMC Brandes U.S. Small-Mid Cap Value ETF

Brandes U.S. Small-Mid Cap Value ETF (BSMC) currently reports 67 stock positions (subject to change), placing it in the neither concentrated nor index-like range by holdings breadth. The top line-up is XRAY (3.32%), IMKTA (3.09%), ELAN (3.09%), with XRAY as the largest single weight at 3.32%. Together, the top three holdings account for 9.50%, which indicates that idiosyncratic risk at the top of the book is relatively contained within the overall portfolio. The resulting profile combines thematic conviction with varying degrees of diversification, which can support upside participation while still spreading idiosyncratic risk beyond the top weights.

From a returns-on-capital standpoint, ROIC is 10.02%, WACC is 7.49%, and the economic spread is 2.53%. On balance, the portfolio clears its capital cost hurdle modestly — value creation is present but not emphatic. Supporting metrics show ROE at 6.78% and ROA at 4.58%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio that is value-creative but with less room for execution slippage.

The market currently prices the portfolio at trailing P/E of 18.33, forward P/E of 12.65, PEG of 4.32. The trailing and forward multiples diverge by a moderate amount, consistent with a market that sees improving earnings but is not extrapolating an aggressive growth path. The PEG ratio signals premium pricing — the portfolio's earnings growth expectations, while present, do not fully explain the current multiple on a purely quantitative basis. The aggregate current ratio of 2.18 points to adequate liquidity across holdings. Valuation and liquidity together frame a portfolio where the price paid today is a reasonable bet on earnings delivery — but not a margin-of-safety purchase at current levels.

On profitability at each income statement layer, gross margin sits at 40.04%, operating margin at 13.12%, and free cash flow margin at 10.66%. The portfolio's gross margins are solid, reflecting a reasonable balance between revenue realization and direct cost absorption. The operating margin reading is modest, consistent with businesses still working to scale their cost structures efficiently. Free cash flow margins are moderate, with a meaningful but not exceptional share of revenue converting to cash after capex. Taken together, the margin stack suggests quality that is uneven — some layers are more resilient than others, and that asymmetry matters under stress.

Looking at growth and market-implied direction, TTM revenue growth of 12.01% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 13.21%, where implied upside appears constructive but not aggressive. It's worth distinguishing between what businesses are actually delivering and what the market is being asked to believe about the next 12 months. Maintaining alignment between reported results and forward estimates is particularly important in periods where macro uncertainty is elevated. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Putting the pieces together, this is a profile with genuine merit: the numbers support confidence in the forward case without requiring heroic assumptions.

The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.